Loading…
Loading…
BLLN (BillionToOne, Inc.) is a recent IPO.
It began trading on November 6, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.
New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals.
The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1.0 million on the August 25, 2026 transaction date. Following the disposal, the insider holds a direct position of 1,000 shares, which represents approximately 0.0022% of the company's total shares outstanding.
/C O R R E C T I O N -- BillionToOne/ PR Newswire MENLO PARK, Calif., Aug. 18, 2026 I
Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results MENLO PARK, Calif., Aug. 18, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal.
Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company.
BillionToOne experienced a sharp post-earnings sell-off despite maintaining full-year guidance and strong year-over-year revenue growth. Second quarter results showed slowing sequential growth, softer average selling prices, and significant margin compression versus Q1. The company trades at ~10x sales, a premium to May levels, with the growth story intact but near-term valuation less attractive.
While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
No recent filings indexed.